Karthik Rajan

Senior Clinical Fellow

Morriston Hospital, Swansea, Wales.

JOURNAL REVIEWED: BJU INTERNATIONAL – March 2020 – December 2022

Latest Contribution

Outcomes of sarcomatoid differentiation in urothelial carcinoma

5 December 2022 | | Urologic Oncology | #BladderCancer, #scmsm, #uroonc, bladder cancer, neoadjuvant therapy, pathological outcomes, sarcomatoid differentiation, survival, urothelial carcinoma

Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...

PIRADS-3 lesions and clinically significant prostate cancer – what are we missing?

5 December 2022 | | Urologic Oncology | MRI, biopsy, fusion biopsies, prostate cancer, radical prostatectomy, risk, systematic biopsies, targeted biopsies

The use of pre-biopsy MRI has definitely enhanced our decision making in managing patients with suspected prostate cancer (PCa). There is still uncertainty around the outcomes for patients with PIRADS-3 lesions, with a small but definite risk of missing clinically...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | Urologic Oncology | #BladderCancer, #blcsm, cytosine arabinoside, intravesical therapy, mitomycin C, non-muscle-invasive bladder cancer, randomised trial, #uroonc, urinary pH

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...